摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Phenyl-5-(1-(2-(pyrrolidine-1-yl)ethyl)-1H-indazol-5-yl)furo[3,2-c]pyridine-4(5H)-one | 1039042-01-7

中文名称
——
中文别名
——
英文名称
2-Phenyl-5-(1-(2-(pyrrolidine-1-yl)ethyl)-1H-indazol-5-yl)furo[3,2-c]pyridine-4(5H)-one
英文别名
2-phenyl-5-[1-(2-pyrrolidin-1-ylethyl)indazol-5-yl]furo[3,2-c]pyridin-4-one
2-Phenyl-5-(1-(2-(pyrrolidine-1-yl)ethyl)-1H-indazol-5-yl)furo[3,2-c]pyridine-4(5H)-one化学式
CAS
1039042-01-7
化学式
C26H24N4O2
mdl
——
分子量
424.502
InChiKey
AZTUEMJLQCTRMN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    32
  • 可旋转键数:
    5
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    54.5
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-Phenyl-5-(1-(2-(pyrrolidine-1-yl)ethyl)-1H-indazol-5-yl)furo[3,2-c]pyridine-4(5H)-one盐酸二氯甲烷乙醚 为溶剂, 反应 1.0h, 以to yield the title compound (14.6 mg, 48%) as a brown solid的产率得到2-Phenyl-5-(1-(2-(pyrrolidine-1-yl)ethyl)-1H-indazol-5-yl)furo[3,2-c]pyridine-4(5H)-one Hydrochloride
    参考文献:
    名称:
    5-FUROPYRIDINONE SUBSTITUTED INDAZOLES
    摘要:
    揭示了化合物。这些化合物作为MCH1调节剂。还揭示了其他实施例。
    公开号:
    US20090318439A1
  • 作为产物:
    参考文献:
    名称:
    5-(Pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists
    摘要:
    A new series of 5-(pyridinon-1-yl)indazoles with MCH-1 antagonist activity were synthesized. Potential cardiovascular risk for these compounds was assessed based upon their interaction with the hERG potassium channel in a mini-patch clamp assay. Selected compounds were studied in a 5-day diet-induced obese mouse model to evaluate their potential use as weight loss agents. Structural modification of the 5-(pyridinon-1-yl) indazoles to give 5-(furopyridinon-5-yl) indazoles provided compounds with enhanced pharmacokinetic properties and improved efficacy. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.09.039
点击查看最新优质反应信息

文献信息

  • 5-FUROPYRIDINONE SUBSTITUTED INDAZOLES
    申请人:Guzzo Peter Robert
    公开号:US20090318439A1
    公开(公告)日:2009-12-24
    Compounds are disclosed. The compounds act as MCH1 modulators. Other embodiments are also disclosed.
    揭示了化合物。这些化合物作为MCH1调节剂。还揭示了其他实施例。
  • US8101632B2
    申请人:——
    公开号:US8101632B2
    公开(公告)日:2012-01-24
  • [EN] 5-FUROPYRIDINONE SUBSTITUTED INDAZOLES<br/>[FR] INDAZOLES SUBSTITUÉS PAR LA 5-FLUOROPYRIDINONE
    申请人:AMR TECHNOLOGY INC
    公开号:WO2008086409A1
    公开(公告)日:2008-07-17
    [EN] Compounds are disclosed. The compounds act as MCH1 modulators. Other embodiments are also disclosed.
    [FR] L'invention concerne des composés qui agissent comme des modulateurs du MCH1. D'autres modes de réalisation sont également décrits.
  • 5-(Pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists
    作者:Matthew D. Surman、Emily E. Freeman、James F. Grabowski、Mark Hadden、Alan J. Henderson、Guowei Jiang、Xiaowu (May) Jiang、Michele Luche、Yuri Khmelnitsky、Steven Vickers、Jean Viggers、Sharon Cheetham、Peter R. Guzzo
    DOI:10.1016/j.bmcl.2010.09.039
    日期:2010.12
    A new series of 5-(pyridinon-1-yl)indazoles with MCH-1 antagonist activity were synthesized. Potential cardiovascular risk for these compounds was assessed based upon their interaction with the hERG potassium channel in a mini-patch clamp assay. Selected compounds were studied in a 5-day diet-induced obese mouse model to evaluate their potential use as weight loss agents. Structural modification of the 5-(pyridinon-1-yl) indazoles to give 5-(furopyridinon-5-yl) indazoles provided compounds with enhanced pharmacokinetic properties and improved efficacy. (C) 2010 Elsevier Ltd. All rights reserved.
  • 5-furopyridinone substituted indazoles
    申请人:Albany Molecular Research, Inc.
    公开号:US08101632B2
    公开(公告)日:2012-01-24
    Compounds are disclosed. The compounds act as MCH1 modulators. Other embodiments are also disclosed.
    本文披露了化合物。这些化合物作为MCH1调节剂。还披露了其他实施方案。
查看更多